Clinical trials: Rhinoconjunctivitis Due to Grass Pollen Allergy
- Condition Rhinoconjunctivitis Due to Grass Pollen Allergy
- Funder type Industry (pharma, biotech, devices)
Allergic Rhinitis
A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- NCT02557633
- Testing
- Grass MATA MPL 10200, Grass MATA MPL 18200
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Allergy Therapeutics
Allergic Rhinitis Due to Grass Pollen
Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber
The aim of this study is to determine the optimal concentration of grass pollen allergens inducing rhinoconjunctivitis in subjects allergic to grass pollen in ALYATEC allergen exposure chamber.
- Trial name
- NCT06104293
- Testing
- Grass Pollen Allergen Exposure
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Alyatec
Allergic Rhinitis Due to Grass Pollens
Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate
This trial is an exploratory randomised, parallel-group, double-blind, placebo- controlled, national, single-centre trial. The trial will be initiated before 2013 grass pollen season and subjects will be randomised in September…
- Trial name
- NCT01854736
- Testing
- Grazax
- Where
- 2 sites in Spain
- Volunteers
- 51 people
- Sponsor
- ALK-Abelló A/S
Hypersensitivity
Safety and Efficacy of an Allergen Vaccine in Grass-Pollen Allergy
The purpose of this study is to evaluate whether the use of a specific immunomodulatory principle (QbG10) together with conventional grass pollen allergen leads to a more rapid and more pronounced decrease of sensitivity against…
- Trial name
- NCT00293904
- Testing
- CYT005-AllQbG10
- Where
- Switzerland
- Volunteers
- 36 people
- Sponsor
- Cytos Biotechnology AG
Seasonal Allergic Rhinitis
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- G104 (NCT03931993)
- Testing
- Grass MATA MPL
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allergy Therapeutics